ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alkermes
ClinicalTrials.gov Identifier:
NCT00678418
First received: May 14, 2008
Last updated: January 11, 2012
Last verified: January 2012

May 14, 2008
January 11, 2012
June 2008
October 2009   (final data collection date for primary outcome measure)
Percentage (%) of Opioid-free Weeks Per Subject in Double-blind Period (Part A) [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]
Included are data from the last 20 weeks of the 24-week double-blind treatment period (Part A). Response profiles for each Arm are based on subjects' individual rates of weekly opioid-free data, including negative urine test results, attendance at study visits, and self-reports of opioid use/non-use.
Response profile based on the rate of positive urine drug test results during the last 20 weeks of the 24-week double-blind treatment period. [ Time Frame: 20 Weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00678418 on ClinicalTrials.gov Archive Site
  • Days to Discontinuation During Part A [ Time Frame: 168 days (24 weeks) ] [ Designated as safety issue: No ]
    Defined as the duration of study participation and calculated as the number of days from Dose 1 to the day of study discontinuation.
  • Craving Score: Change From Baseline [ Time Frame: Baseline to 6 months (24 weeks) ] [ Designated as safety issue: No ]
    Measured using subjects' response on a validated Visual Analog Scale at prespecified weekly visits throughout Part A, with comparison of baseline to end of Part A. The scale ranged from 0 ("No craving") to 100 ("highest possible craving").
  • Incidence of Subjects Who Relapsed to Physiologic Opioid Dependence During the 24-week Treatment Period (Part A) [ Time Frame: 24 Weeks ] [ Designated as safety issue: No ]
    Assessment of relapse to physiologic opioid dependence was based on individual subjects' results on the naloxone challenge test. A positive naloxone challenge test result was considered as a relapse to physiologic opioid dependence.
  • Change in Percentage of Self-reported Opioid-free Days From Baseline to Week 24 [ Time Frame: 24 Weeks ] [ Designated as safety issue: No ]
    Opioid use was measured using subjects' entries on a validated Timeline FollowBack (TLFB) calendar in which they recorded their use/non-use of opioids each day.
  • Study retention during the double-blind period [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Craving score [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
  • Incidence of physiologic opioid dependence (physiologic dependence is defined as a positive naloxone challenge) [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
  • Self-reported opioid use [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence
Efficacy and Safety of VIVITROL® (Naltrexone for Extended-release Injectable Suspension) in Adults With Opioid Dependence

This is a Phase 3 multi-center trial designed to evaluate the clinical efficacy and safety of VIVITROL® (Medisorb® naltrexone 380 mg) versus placebo when administered to adults upon discharge from inpatient treatment for opioid dependence.

The study was conducted in 2 parts, Part A and Part B. The clinical portion of both parts has completed. Results for Part B are not yet available.

Part A was a double-blind, randomized, placebo-controlled assessment of the efficacy and safety of 24 weeks of monthly treatment with VIVITROL compared to placebo in opioid-dependent adults.

Subjects who completed Part A could choose to continue to Part B, which was an open-label extension to assess longer-term safety, durability of effect, health economics, and quality of life (QOL) in the continuing study population for up to 1 year.

At the conclusion of both parts, each completing subject will have received a total of up to 19 injections of study drug over approximately 1.5 years.

Dosing was performed by the principal investigator or designated study staff member.

All subjects received standardized, manual-based psychosocial support at each scheduled visit. Opioid use was tracked through urine drug testing and subjects' self reports. Other evaluations for efficacy and safety, health economics, and quality of life were routinely conducted throughout the study.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Opiate Dependence
  • Drug: VIVITROL® 380 mg
    Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
    Other Names:
    • Naltrexone for extended-release injectable suspension
    • Medisorb® naltrexone
  • Drug: Placebo
    Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
  • Experimental: VIVITROL® 380 mg
    Intervention: Drug: VIVITROL® 380 mg
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
250
November 2010
October 2009   (final data collection date for primary outcome measure)

Primary Inclusion Criteria:

  • Written, informed consent
  • 18 years of age or older
  • Current diagnosis of opioid dependence, based on Diagnostic and Statistical Manual of Mental Health Disorders, 4th Ed. (DSM-IV-TR) criteria
  • Voluntarily seeking treatment for opioid dependence
  • Completing or recently completed up to 30 days of inpatient treatment for opioid detoxification, and off all opioids (including buprenorphine and methadone) for at least 7 days
  • Noncustodial, stable residence and phone, plus 1 contact with verifiable address and phone
  • Significant other (eg, spouse, relative) willing to supervise compliance with the study visit schedule and procedures
  • Agree to use contraception for study duration if of childbearing potential

Primary Exclusion Criteria:

  • Pregnancy or lactation
  • Clinically significant medical condition or observed abnormalities (eg: physical exam, electrocardiogram (ECG), lab and/or urinalysis findings)
  • Positive naloxone challenge test at randomization (Day 0)
  • Evidence of hepatic failure including: ascites, bilirubin >10% above upper limit of normal (ULN) and/or esophageal variceal disease
  • Past or present history of an acquired immunodeficiency syndrome (AIDS)-indicator disease in HIV-infected subjects
  • Active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase(ALT) >3xULN
  • Current major depression with suicidal ideation, psychosis, bipolar disorder, or any psychiatric disorder that would compromise ability to complete the study
  • Recent history (within 6 months prior to screening) of suicidal ideation or attempt
  • Dependence within prior year based on DSM-IV-TR, to any drugs other than prescription opioids or heroin, caffeine, marijuana, or nicotine
  • Active alcohol dependence within prior 6 months
  • Current alcohol use disorder that would, in the Investigator's opinion, preclude successful completion of the study
  • Positive urine drug test for cocaine, benzodiazepines, or amphetamines at screening
  • Use of oral naltrexone for 7 consecutive days within 60 days prior to screening
  • Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-glycolide (PLG)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Russian Federation
 
NCT00678418
ALK21-013
No
Alkermes
Alkermes
Not Provided
Principal Investigator: Evgeny Krupitsky, Prof. Leningrad Regional Addiction Center
Principal Investigator: Ruslan Ilyuk, Dr. Bekhterev Psychoneurological Research Institute
Principal Investigator: Edvin Zvartau, Prof. Saint-Petersburg State Medical University n.a. Pavlov
Principal Investigator: Alexander Sofronov, Prof. Saint-Petersburg Addiction Hospital
Principal Investigator: Alexey Egorov, Prof. Saint-Petersburg Addiction Hospital
Principal Investigator: Alexander Okhapkin, Prof. Addiction Treatment Center, Clinical Facility of Smolensk State Medical Academy
Principal Investigator: Nikolay Bokhan, Prof. Tomsk Mental Health Research Institute
Principal Investigator: Vladimir Mendelevich, Prof. Kazan State Medical University
Principal Investigator: Yuri Sivolap, Prof. Moscow Medical Academy n.a. I.M. Sechenov
Principal Investigator: Oleg Eryshev, Prof. Bekhterev Psychoneurological Research Institute
Principal Investigator: Nikolay Ivanets, Prof. National Addiction Scientific Center
Principal Investigator: Vitaliy Sinitskiy, Prof. Northern State Medical University
Principal Investigator: Andrey Anipchenko, Dr. Saint-Petersburg Addiction Hospital
Alkermes
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP